-
Deep brain stimulation significantly increases "on" time, reduces dyskinesias, reduces "off" time, and improves various quality-of-life measures compared with best medical therapy in patients with moderate to advanced Parkinson's disease.
-
Utilizing genotyping for warfarin therapy in patients with non-valvular atrial fibrillation may not be cost-effective.
-
A prospective study of men and women showed that duration of sleep is correlated with coronary artery calcification with 1 hour more of sleep daily reducing the odds of calcification over 5 years by 33%.
-
-
The first new urate-lowering drug has been approved in more than 40 years.
-
The FDA is considering new tightened restrictions on use of opioid drugs. Manufacturers of these drugs will be required to have a Risk Evaluation and Mitigation Strategy to ensure that "the benefits of the drugs continue to outweigh the risks."
-
Get used to the word "pharmacogenetics" — the discipline of studying genetic variation and its effect on responses to drugs.
-
-
The FDA has issued a public health advisory regarding the risk of progressive multifocal leukoencephalopathy (PML) associated with use of efalizumab (Raptiva®) for the treatment of psoriasis.
-
Rate control vs rhythm control for atrial fibrillation continues to be debated with most of the evidence falling on the side of rate control in recent years, primarily because of adverse effects from anti-arrhythmics. A new drug may change that however.